These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Calbo E; Alsina M; Rodríguez-Carballeira M; Lite J; Garau J Antimicrob Agents Chemother; 2008 Jul; 52(7):2395-402. PubMed ID: 18426893 [TBL] [Abstract][Full Text] [Related]
3. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269 [TBL] [Abstract][Full Text] [Related]
4. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. Olive D; Georges H; Devos P; Boussekey N; Chiche A; Meybeck A; Alfandari S; Leroy O BMC Infect Dis; 2011 Mar; 11():66. PubMed ID: 21406091 [TBL] [Abstract][Full Text] [Related]
5. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Falagas ME; Siempos II; Bliziotis IA; Panos GZ Mayo Clin Proc; 2006 Dec; 81(12):1567-74. PubMed ID: 17165635 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment outcomes in community-acquired pneumonia. Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147 [TBL] [Abstract][Full Text] [Related]
7. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Mortensen EM; Restrepo MI; Anzueto A; Pugh J Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641 [TBL] [Abstract][Full Text] [Related]
8. Antibiotic treatment strategies for community-acquired pneumonia in adults. Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ; N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421 [TBL] [Abstract][Full Text] [Related]
9. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451 [TBL] [Abstract][Full Text] [Related]
10. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia. Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336 [TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Raz-Pasteur A; Shasha D; Paul M Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096 [TBL] [Abstract][Full Text] [Related]
13. [Guidelines for treatment of pneumonia in intensive care units]. Emmi V Infez Med; 2005; Suppl():7-17. PubMed ID: 16801748 [TBL] [Abstract][Full Text] [Related]
14. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460 [TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ; BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis. De la Calle C; Ternavasio-de la Vega HG; Morata L; Marco F; Cardozo C; García-Vidal C; Del Rio A; Cilloniz C; Torres A; Martínez JA; Mensa J; Soriano A J Infect; 2018 Apr; 76(4):342-347. PubMed ID: 29360520 [TBL] [Abstract][Full Text] [Related]
18. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Vallès X; Marcos A; Pinart M; Piñer R; Marco F; Mensa JM; Torres A Chest; 2006 Sep; 130(3):800-6. PubMed ID: 16963678 [TBL] [Abstract][Full Text] [Related]
19. The dilemma of monotherapy or combination therapy in community-acquired pneumonia. Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. Yoshioka D; Kajiwara C; Ishii Y; Umeki K; Hiramatsu K; Kadota J; Tateda K Antimicrob Agents Chemother; 2016 Oct; 60(10):6146-54. PubMed ID: 27480866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]